Brainaxy Clinic S.R.L.

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• CIDP (chronic inflammatory demyelinating polyneuropathy)4 trials
• Myasthenia gravis2 trials
• Alzheimer disease1 trial

Phase

• Phase 35 trials
• Phase 22 trials

Status

• Recruiting6 trials
• Completed1 trial

Lead sponsor

• Immunovant Sciences GmbH3 trials
• argenx1 trial
• Bristol-Myers Squibb1 trial
• Dianthus Therapeutics Inc.1 trial
• Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1 trial

Running trials

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

  2024-517529-26-00· Phase 3· Dianthus Therapeutics Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  NCT06976203· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

  NCT07039916· Phase 3· Immunovant Sciences GmbH· Source

• Recruiting

  Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT07032662· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Myasthenia gravis2 recruiting
• Alzheimer disease1 recruiting

Closed trials

• Completed

  A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP

  2024-518364-12-00· Phase 2· Immunovant Sciences GmbH· Source